Boosted classification trees result in minor to modest improvement in the accuracy in classifying cardiovascular outcomes compared to conventional classification trees.

PURPOSE Classification trees are increasingly being used to classifying patients according to the presence or absence of a disease or health outcome. A limitation of classification trees is their limited predictive accuracy. In the data-mining and machine learning literature, boosting has been developed to improve classification. Boosting with classification trees iteratively grows classification trees in a sequence of reweighted datasets. In a given iteration, subjects that were misclassified in the previous iteration are weighted more highly than subjects that were correctly classified. Classifications from each of the classification trees in the sequence are combined through a weighted majority vote to produce a final classification. The authors' objective was to examine whether boosting improved the accuracy of classification trees for predicting outcomes in cardiovascular patients. METHODS We examined the utility of boosting classification trees for classifying 30-day mortality outcomes in patients hospitalized with either acute myocardial infarction or congestive heart failure. RESULTS Improvements in the misclassification rate using boosted classification trees were at best minor compared to when conventional classification trees were used. Minor to modest improvements to sensitivity were observed, with only a negligible reduction in specificity. For predicting cardiovascular mortality, boosted classification trees had high specificity, but low sensitivity. CONCLUSIONS Gains in predictive accuracy for predicting cardiovascular outcomes were less impressive than gains in performance observed in the data mining literature.

[1]  K. Swedberg,et al.  Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial). , 2012, The American journal of cardiology.

[2]  V. Roger,et al.  Comorbidity and Ventricular and Vascular Structure and Function in Heart Failure With Preserved Ejection Fraction: A Community-Based Study , 2012, Circulation. Heart failure.

[3]  D. J. Veldhuisen,et al.  Comparing New Onset Heart Failure with Reduced Ejection Fraction and New Onset Heart Failure with Preserved Ejection Fraction: An Epidemiologic Perspective , 2012, Current Heart Failure Reports.

[4]  R. McKelvie,et al.  Sex Differences in Clinical Characteristics and Outcomes in Elderly Patients With Heart Failure and Preserved Ejection Fraction: The Irbesartan in Heart Failure With Preserved Ejection Fraction (I-PRESERVE) Trial , 2012, Circulation. Heart failure.

[5]  R. Sacco,et al.  Arterial Stiffness and Wave Reflection: Sex Differences and Relationship With Left Ventricular Diastolic Function , 2012, Hypertension.

[6]  A. Kaya,et al.  Impact of Body Mass Index on Left Ventricular Diastolic Dysfunction , 2012, Echocardiography.

[7]  J. McMurray,et al.  Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta‐analysis † , 2012, European journal of heart failure.

[8]  P. Macfarlane,et al.  Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. , 2012, The Journal of clinical endocrinology and metabolism.

[9]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[10]  R. Jurcuț,et al.  A personalized medicine target: heart failure in women , 2011, Journal of medicine and life.

[11]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[12]  Wei-Yin Loh,et al.  Classification and regression trees , 2011, WIREs Data Mining Knowl. Discov..

[13]  Michael Böhm,et al.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.

[14]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[15]  K. Dickstein,et al.  Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial , 2009, The Lancet.

[16]  I. Piña,et al.  Heart failure in women: a need for prospective data. , 2009, Journal of the American College of Cardiology.

[17]  L. Leinwand,et al.  Sex-based cardiac physiology. , 2009, Annual review of physiology.

[18]  D. Korzick,et al.  Rapid estrogen receptor-alpha activation improves ischemic tolerance in aged female rats through a novel protein kinase C epsilon-dependent mechanism. , 2009, Endocrinology.

[19]  K. Swedberg,et al.  Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry. , 2008, European heart journal.

[20]  R. Ferrari,et al.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[21]  V. Hasselblad,et al.  Cardiorenal interactions: insights from the ESCAPE trial. , 2008, Journal of the American College of Cardiology.

[22]  K. Furie,et al.  Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2008, Circulation.

[23]  L. Leinwand,et al.  The effects of biological sex and diet on the development of heart failure. , 2007, Circulation.

[24]  Peter Buhlmann,et al.  BOOSTING ALGORITHMS: REGULARIZATION, PREDICTION AND MODEL FITTING , 2007, 0804.2752.

[25]  P. Poole‐Wilson,et al.  Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. , 2007, American heart journal.

[26]  S. Solomon,et al.  Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure: Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program , 2007, Circulation.

[27]  M. Walsh,et al.  Low rate of sex-specific result reporting in cardiovascular trials. , 2007, Mayo Clinic proceedings.

[28]  P. Austin A comparison of classification and regression trees, logistic regression, generalized additive models, and multivariate adaptive regression splines for predicting AMI mortality , 2007 .

[29]  Mark Culp,et al.  ada: An R Package for Stochastic Boosting , 2006 .

[30]  D. Hinkley Annals of Statistics , 2006 .

[31]  A. Tsiatis,et al.  Cost-Effectiveness of Defibrillator Therapy or Amiodarone in Chronic Stable Heart Failure: Results From the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) , 2006, Circulation.

[32]  G. Fonarow,et al.  Gender differences in in-hospital management and outcomes in patients with decompensated heart failure: analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). , 2006, Journal of cardiac failure.

[33]  A. Moss,et al.  Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. , 2006, Journal of the American College of Cardiology.

[34]  A. Owen Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. , 2005, European heart journal.

[35]  D. Kass,et al.  Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. , 2005, Journal of the American College of Cardiology.

[36]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[37]  G. Biondi-Zoccai,et al.  Reduced post-infarction myocardial apoptosis in women: a clue to their different clinical course? , 2003, Heart.

[38]  J. Daubert,et al.  Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. , 2006, European heart journal.

[39]  M. Cavasin,et al.  Gender differences in cardiac function during early remodeling after acute myocardial infarction in mice. , 2004, Life sciences.

[40]  B. Yawn,et al.  Trends in heart failure incidence and survival in a community-based population. , 2004, JAMA.

[41]  D. Ruppert The Elements of Statistical Learning: Data Mining, Inference, and Prediction , 2004 .

[42]  W. Kannel,et al.  Incidence and Epidemiology of Heart Failure , 2000, Heart Failure Reviews.

[43]  R. Redberg,et al.  Gender and valvular surgery. , 2004, The Journal of thoracic and cardiovascular surgery.

[44]  J. López-Sendón,et al.  The EPHESUS Trial: Eplerenone in Patients with Heart Failure Due to Systolic Dysfunction Complicating Acute Myocardial Infarction , 2004, Cardiovascular Drugs and Therapy.

[45]  S. Lemon,et al.  Classification and regression tree analysis in public health: Methodological review and comparison with logistic regression , 2003, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[46]  S. A. Gansky,et al.  Dental Data Mining: Potential Pitfalls and Practical Issues , 2003, Advances in dental research.

[47]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[48]  M. Pfeffer,et al.  VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context , 2003, European journal of heart failure.

[49]  Jeffrey L. Anderson,et al.  Failure of benefit and early hazard of bucindolol for Class IV heart failure. , 2003, Journal of cardiac failure.

[50]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[51]  N. Freemantle,et al.  The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment , 2003 .

[52]  N Freemantle,et al.  The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. , 2003, European heart journal.

[53]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[54]  M. Lauer,et al.  The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. , 2002, Journal of the American College of Cardiology.

[55]  J. Tu,et al.  Prognosis and Determinants of Survival in Patients Newly Hospitalized for Heart Failure: A Population-Based Study , 2002 .

[56]  Heinrich Taegtmeyer,et al.  Obesity and the risk of heart failure. , 2002, The New England journal of medicine.

[57]  A. Jacobs,et al.  Absence of gender differences in clinical outcomes in patients with cardiogenic shock complicating acute myocardial infarction. A report from the SHOCK Trial Registry. , 2001, Journal of the American College of Cardiology.

[58]  A. Tedgui,et al.  Age and gender effects on cardiomyocyte apoptosis in the normal human heart. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.

[59]  E. Levin highlighted topics Genome and Hormones: Gender Differences in Physiology Invited Review: Cell localization, physiology, and nongenomic actions of estrogen receptors , 2001 .

[60]  Jennifer Y. Liu,et al.  Glycemic Control and Heart Failure Among Adult Patients With Diabetes , 2001, Circulation.

[61]  A. Clerk,et al.  Akt like a woman: gender differences in susceptibility to cardiovascular disease. , 2001, Circulation research.

[62]  Mark A Sussman,et al.  Myocardial Akt Activation and Gender: Increased Nuclear Activity in Females Versus Males , 2001, Circulation research.

[63]  K. Dickstein,et al.  Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan. , 2001, The American journal of cardiology.

[64]  T. Simon,et al.  Sex Differences in the Prognosis of Congestive Heart Failure: Results From the Cardiac Insufficiency Bisoprolol Study (CIBIS II) , 2001, Circulation.

[65]  Trevor Hastie,et al.  The Elements of Statistical Learning , 2001 .

[66]  J. Cohn,et al.  Baseline demographics of the Valsartan Heart Failure Trial , 2000, European journal of heart failure.

[67]  D. R. Gross,et al.  Effect of estrogen on global myocardial ischemia-reperfusion injury in female rats. , 2000, American journal of physiology. Heart and circulatory physiology.

[68]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[69]  Bertram Pitt,et al.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.

[70]  B. Vanhaesebroeck,et al.  The PI3K-PDK1 connection: more than just a road to PKB. , 2000, The Biochemical journal.

[71]  P A Poole-Wilson,et al.  Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.

[72]  C. di Loreto,et al.  Myocyte death in the failing human heart is gender dependent. , 1999, Circulation research.

[73]  M. Kostkiewicz,et al.  Left ventricular geometry and function in patients with aortic stenosis: gender differences. , 1999, International journal of cardiology.

[74]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[75]  P. Douglas,et al.  Gender differences in molecular remodeling in pressure overload hypertrophy. , 1999, Journal of the American College of Cardiology.

[76]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[77]  G. Koch,et al.  Gender differences in survival in advanced heart failure. Insights from the FIRST study. , 1999, Circulation.

[78]  M. Greenberg,et al.  Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor , 1999, Cell.

[79]  CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[80]  John Bell,et al.  Tree-based methods , 1999 .

[81]  W Sauerbrei,et al.  Differentiation of Benign and Malignant Breast Tumors by Logistic Regression and a Classification Tree using Doppler flow signals , 1998, Methods of Information in Medicine.

[82]  Ping H Wang,et al.  Insulin-like growth factor I modulates induction of apoptotic signaling in H9C2 cardiac muscle cells , 1998 .

[83]  D A Bloch,et al.  Recursive partitioning for the identification of disease risk subgroups: a case-control study of subarachnoid hemorrhage. , 1998, Journal of clinical epidemiology.

[84]  R. Karas,et al.  Cardiac myocytes and fibroblasts contain functional estrogen receptors 1 , 1997, FEBS letters.

[85]  A. Koller,et al.  Gender difference in myogenic tone of rat arterioles is due to estrogen-induced, enhanced release of NO. , 1997, The American journal of physiology.

[86]  Elizabeth Yang,et al.  Serine Phosphorylation of Death Agonist BAD in Response to Survival Factor Results in Binding to 14-3-3 Not BCL-XL , 1996, Cell.

[87]  P. Petrusz,et al.  Estradiol stimulates tyrosine phosphorylation of the insulin-like growth factor-1 receptor and insulin receptor substrate-1 in the uterus. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[88]  Yoav Freund,et al.  Experiments with a New Boosting Algorithm , 1996, ICML.

[89]  P. Anversa,et al.  Gender differences and aging: effects on the human heart. , 1995, Journal of the American College of Cardiology.

[90]  Daniel L. McGee,et al.  Left ventricular hypertrophy has a greater impact on survival in women than in men. , 1995, Circulation.

[91]  D. Levy,et al.  Sex differences in cardiac adaptation to isolated systolic hypertension. , 1993, The American journal of cardiology.

[92]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[93]  D. Herrington,et al.  Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. , 1992, Journal of the American College of Cardiology.

[94]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[95]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[96]  J. Scheuer,et al.  Effects of gonadectomy and hormonal replacement on rat hearts. , 1987, Circulation research.

[97]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[98]  M. Pfeffer,et al.  Favorable effects of therapy on cardiac performance in spontaneously hypertensive rats. , 1982, The American journal of physiology.